Wasazra Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 13-12-2024
- Paid Up Capital ₹ 1.00 M
as on 13-12-2024
- Company Age 7 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 129.70%
(FY 2022)
- Profit 133.81%
(FY 2022)
- Ebitda 19.56%
(FY 2022)
- Net Worth 33.85%
(FY 2022)
- Total Assets 63.53%
(FY 2022)
About Wasazra Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Azra Waseem, Nida Fatima, Firdaus Fatima, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909UP2017PLC093735
- Company No.
093735
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
01 Jun 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Lucknow, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media
What products or services does Wasazra Pharmaceuticals Limited offer?
Wasazra Pharmaceuticals Limited offers a wide range of products and services, including Stock Trading/Money Market, Currency Trading Services.
Who are the key members and board of directors at Wasazra Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sayed Hashmi  | Managing Director | 01-Jun-2017 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Azra Waseem | Director | 01-Jun-2017 | Current |
| Nida Fatima | Director | 01-Jun-2017 | Current |
| Firdaus Fatima | Director | 01-Jun-2017 | Current |
Financial Performance of Wasazra Pharmaceuticals.
Wasazra Pharmaceuticals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 129.7% increase. The company also saw a substantial improvement in profitability, with a 133.81% increase in profit. The company's net worth Soared by an impressive increase of 33.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wasazra Pharmaceuticals?
Unlock access to Wasazra Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Wasazra Pharmaceuticals?
Unlock and access historical data on people associated with Wasazra Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wasazra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wasazra Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
